Propanc Biopharma, Inc. — Form S-1
Filed October 5, 2026 · analyzed by the Registration Agent
S-1
— Neutral
significance 42/100
What the filing says
Propanc Biopharma filed Form S-1 on October 5, 2026 to register 6,500,000 common shares ($0.001 par value) issuable to a Selling Stockholder upon conversion of Series C Preferred Stock. The filing is a legal registration statement with standard counsel and auditor opinions (Brunson Chandler Jones, PLLC and Salberg Company, P.A.); no conversion price, financing amount, or dilution percentage is disclosed in this exhibit.
Why this rating
Series C conversion of 6.5M shares to ~$2.7M-market-cap company is meaningful dilution, but lacks detail on economics. Standard S-1 routine.
See more from October 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.